"TBSF" Human Immunoglobulin for Intravenous Use

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

normal immunoglobulin, Quantity: 60 g/L

Inapatikana kutoka:

CSL Behring Australia Pty Ltd

INN (Jina la Kimataifa):

normal immunoglobulin

Dawa fomu:

Injection, solution

Tungo:

Excipient Ingredients: maltose

Njia ya uendeshaji:

Intravenous

Vitengo katika mfuko:

50mL, 200mL

Darasa:

Medicine Listed (Export Only)

Dawa ya aina:

(S1) This Schedule is intentionally blank

Matibabu dalili:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Bidhaa muhtasari:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Idhini hali ya:

Listed (Export Only)

Idhini ya tarehe:

2006-03-01